KR100706727B1 - 중증 심부전의 치료방법 및 이를 위한 약제 - Google Patents

중증 심부전의 치료방법 및 이를 위한 약제 Download PDF

Info

Publication number
KR100706727B1
KR100706727B1 KR1020057002579A KR20057002579A KR100706727B1 KR 100706727 B1 KR100706727 B1 KR 100706727B1 KR 1020057002579 A KR1020057002579 A KR 1020057002579A KR 20057002579 A KR20057002579 A KR 20057002579A KR 100706727 B1 KR100706727 B1 KR 100706727B1
Authority
KR
South Korea
Prior art keywords
heart failure
acceptable salt
pharmaceutically acceptable
active compound
benzazepine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020057002579A
Other languages
English (en)
Korean (ko)
Other versions
KR20050105972A (ko
Inventor
아쯔시 오자끼
요스께 마끼
오사무 사또
요시따까 야마무라
Original Assignee
오츠카 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100706727(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오츠카 세이야쿠 가부시키가이샤 filed Critical 오츠카 세이야쿠 가부시키가이샤
Publication of KR20050105972A publication Critical patent/KR20050105972A/ko
Application granted granted Critical
Publication of KR100706727B1 publication Critical patent/KR100706727B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020057002579A 2003-02-24 2004-02-23 중증 심부전의 치료방법 및 이를 위한 약제 Expired - Lifetime KR100706727B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
US60/448,878 2003-02-24

Publications (2)

Publication Number Publication Date
KR20050105972A KR20050105972A (ko) 2005-11-08
KR100706727B1 true KR100706727B1 (ko) 2007-04-12

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057002579A Expired - Lifetime KR100706727B1 (ko) 2003-02-24 2004-02-23 중증 심부전의 치료방법 및 이를 위한 약제

Country Status (23)

Country Link
US (2) US7423032B2 (enExample)
EP (2) EP1596868B1 (enExample)
JP (2) JP4771937B2 (enExample)
KR (1) KR100706727B1 (enExample)
CN (1) CN100577171C (enExample)
AR (1) AR043259A1 (enExample)
AT (1) ATE411803T1 (enExample)
AU (2) AU2004212842B9 (enExample)
BR (1) BRPI0405657A (enExample)
CA (1) CA2493475A1 (enExample)
CY (1) CY1108583T1 (enExample)
DE (1) DE602004017283D1 (enExample)
DK (1) DK1596868T3 (enExample)
ES (1) ES2315640T3 (enExample)
MX (1) MXPA05001623A (enExample)
MY (1) MY143740A (enExample)
NO (1) NO335369B1 (enExample)
PL (2) PL218069B1 (enExample)
PT (1) PT1596868E (enExample)
RU (2) RU2346689C2 (enExample)
SI (1) SI1596868T1 (enExample)
TW (1) TWI322689B (enExample)
WO (1) WO2004073716A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
ES2533007T3 (es) 2005-12-27 2015-04-06 Otsuka Pharmaceutical Co., Ltd. Compuesto de benzoacepina soluble en agua y su composición farmacéutica
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
EP2146721B1 (en) * 2007-05-15 2013-07-10 Otsuka Pharmaceutical Co., Ltd. Methods for using vasopressin antagonists with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
WO2011104269A1 (en) 2008-02-26 2011-09-01 Jenavalve Technology Inc. Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
WO2011147849A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
EP4098226A1 (en) 2013-08-30 2022-12-07 JenaValve Technology, Inc. Endoprosthesis comprising a radially collapsible frame and a prosthetic valve
EP3270825B1 (en) 2015-03-20 2020-04-22 JenaValve Technology, Inc. Heart valve prosthesis delivery system
WO2016177562A1 (en) 2015-05-01 2016-11-10 Jenavalve Technology, Inc. Device and method with reduced pacemaker rate in heart valve replacement
EP4183371A1 (en) 2016-05-13 2023-05-24 JenaValve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
JP7094965B2 (ja) 2017-01-27 2022-07-04 イエナバルブ テクノロジー インク 心臓弁模倣
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用
WO2024102411A1 (en) 2022-11-09 2024-05-16 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157368A (ja) * 1994-12-09 1996-06-18 Otsuka Pharmaceut Co Ltd 脳浮腫治療剤
JPH1121241A (ja) * 1997-07-03 1999-01-26 Otsuka Pharmaceut Co Ltd 固形製剤組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
DE122009000062I2 (de) 1989-10-20 2011-01-13 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
CA2116334A1 (en) 1992-07-02 1994-01-20 Hidenori Ogawa Oxytocin antagonist
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
CA2397244C (en) 2000-01-26 2009-11-17 Warner-Lambert Company Ace inhibitor-vasopressin antagonist combinations
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
ATE367815T1 (de) 2000-10-04 2007-08-15 Astellas Pharma Inc Verwendung von einem vasopressin-antagonisten wie conivaptan zur herstellung eines medikaments für die behandlung der pulmonalen hypertension
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08157368A (ja) * 1994-12-09 1996-06-18 Otsuka Pharmaceut Co Ltd 脳浮腫治療剤
JPH1121241A (ja) * 1997-07-03 1999-01-26 Otsuka Pharmaceut Co Ltd 固形製剤組成物

Also Published As

Publication number Publication date
AU2009201109A1 (en) 2009-04-09
CN100577171C (zh) 2010-01-06
AU2004212842B2 (en) 2009-01-08
KR20050105972A (ko) 2005-11-08
CA2493475A1 (en) 2004-09-02
NO335369B1 (no) 2014-12-01
AR043259A1 (es) 2005-07-20
AU2004212842B9 (en) 2009-03-05
JP2011148806A (ja) 2011-08-04
BRPI0405657A (pt) 2005-07-19
CN1700919A (zh) 2005-11-23
PT1596868E (pt) 2009-01-14
CY1108583T1 (el) 2014-04-09
MY143740A (en) 2011-07-15
TW200418489A (en) 2004-10-01
SI1596868T1 (sl) 2008-12-31
RU2008133654A (ru) 2010-02-20
US7423032B2 (en) 2008-09-09
DK1596868T3 (da) 2008-12-08
EP1596868B1 (en) 2008-10-22
JP2006518731A (ja) 2006-08-17
AU2004212842A1 (en) 2004-09-02
TWI322689B (en) 2010-04-01
PL218069B1 (pl) 2014-10-31
US7749993B2 (en) 2010-07-06
US20050187210A1 (en) 2005-08-25
WO2004073716A1 (en) 2004-09-02
DE602004017283D1 (de) 2008-12-04
EP2000142A1 (en) 2008-12-10
PL404315A1 (pl) 2013-08-05
EP1596868A4 (en) 2006-03-29
RU2346689C2 (ru) 2009-02-20
JP4771937B2 (ja) 2011-09-14
US20080214523A1 (en) 2008-09-04
RU2005102110A (ru) 2005-09-20
ATE411803T1 (de) 2008-11-15
EP1596868A1 (en) 2005-11-23
PL373432A1 (en) 2005-08-22
MXPA05001623A (es) 2005-04-25
NO20050569L (no) 2005-11-22
ES2315640T3 (es) 2009-04-01
HK1084037A1 (zh) 2006-07-21
NO20050569D0 (no) 2005-02-02

Similar Documents

Publication Publication Date Title
KR100706727B1 (ko) 중증 심부전의 치료방법 및 이를 위한 약제
US20240261242A1 (en) Methods of intravenously administering sotalol
TW589184B (en) Pharmaceutical composition for preventing or reversing diabetic cardiomyopathy
AU780152B2 (en) Use of cortisol antagonists in the treatment for heat failure
CN101507726B (zh) 窦房结If电流抑制剂和β-阻滞剂的组合
HK1084037B (en) Medicament for treating severe heart failure
US20240238290A1 (en) Use of complement factor d inhibitor for treatment of generalized myasthenia gravis
JP3002766B2 (ja) 脳浮腫治療剤
WO2025020917A1 (zh) 用于治疗脏器纤维化相关疾病的药物组合物和方法
CN101879167B (zh) 抗高血压药物复方制剂
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
CN112512526A (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
Kim et al. A case of uremic pericarditis and cardiac tamponade that developed after ethylene glycol poisoning: A case report
CN1433302A (zh) 氢化可的松拮抗剂在治疗心力衰竭中的应用
HK1153940A (en) Method of bowel cleansing

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20130321

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20140319

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20160318

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20170302

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 12

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 13

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 14

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 15

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 16

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 17

PC1801 Expiration of term

St.27 status event code: N-4-6-H10-H14-oth-PC1801

Not in force date: 20240224

Ip right cessation event data comment text: Termination Category : EXPIRATION_OF_DURATION